Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Company Overview

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing curative therapies for patients with chronic hepatitis B virus (HBV) infection. Headquartered in Warminster, Pennsylvania, with research and development operations in Vancouver, Canada, Arbutus leverages its proprietary lipid nanoparticle (LNP) delivery platform and RNA interference (RNAi) programs to advance a pipeline of therapies designed to achieve functional cure of HBV.

The company’s lead investigational product, AB-729, is an RNAi therapeutic that targets viral transcripts, aiming to reduce key viral proteins and restore immune control. Arbutus is also developing small-molecule capsid assembly modulators (AB-101 and AB-201) to inhibit viral replication by disrupting the formation of the hepatitis B virus capsid. These programs reflect Arbutus’s integrated approach, combining novel delivery technology with complementary antiviral mechanisms to address multiple stages of the HBV lifecycle.

Since its formation in 2015 through the combination of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus has built a robust intellectual property portfolio covering LNP formulation and formulation components, RNAi chemistries and HBV-related patents. The company maintains strategic collaborations and licensing agreements to extend its platform capabilities and broaden its reach in antiviral development.

Under the leadership of President and Chief Executive Officer Mark J. F. Myers, Arbutus Biopharma is committed to advancing global efforts against chronic hepatitis B. With a presence in North America and partnerships across Europe and Asia, the company seeks to deliver innovative therapies that could transform the treatment landscape and improve outcomes for millions of patients worldwide.

Key Stats

• Today's Range: $3.12 to $3.25
• 50-Day Range: $3.08 to $3.58
• 52-Week Range: $2.71 to $4.73
• Volume: 433,302 shs
• Average Volume: 954,095 shs
• Market Capitalization: $598.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Arbutus Biopharma Stock Analysis - MarketRank™

Arbutus Biopharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 672nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arbutus Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arbutus Biopharma is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arbutus Biopharma is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arbutus Biopharma has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.02% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arbutus Biopharma does not currently pay a dividend.

Dividend Growth

Arbutus Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.02% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Arbutus Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Arbutus Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABUS Stock Analysis - Frequently Asked Questions

How have ABUS shares performed this year?

Arbutus Biopharma's stock was trading at $3.27 at the beginning of 2025. Since then, ABUS stock has decreased by 4.4% and is now trading at $3.1250.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.54 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 75.51% and a negative net margin of 1,196.64%.

Who are Arbutus Biopharma's major shareholders?

Top institutional investors of Arbutus Biopharma include Assenagon Asset Management S.A. (0.02%).
View institutional ownership trends.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABUS
• CIK: 1447028
• Web: www.arbutusbio.com
• Phone: (267) 469-0914
• Fax: 604-419-3201
• Employees: 90
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Arbutus Biopharma: $5.50
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +76.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.92 million
• Net Margins: -1,196.64%
• Pretax Margin: -1,195.86%
• Return on Equity: -75.51%
• Return on Assets: -55.81%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 6.01
• Quick Ratio: 6.01

Sales & Book Value

• Annual Sales: $6.17 million
• Price / Sales: 97.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 6.13

Miscellaneous

• Outstanding Shares: 191,530,000
• Free Float: 152,647,000
• Market Cap: $598.53 million
• Optionable: Optionable
• Beta: 1.20